11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Doxazosin Stada

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Doxazosin

Doxazosin

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Chung M, Vashi V, Puente J, Sweeney M, Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol. 1999;48:678-87.

  2. Kwon YH, Gwak HS, Yoon SJ, Chun IK. Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers. Drug Dev Ind Pharm. 2007;33:824-9.

  3. Clinical Pharmacology and Biopharmaceutics Review - CARDURA XL (doxazosin mesylate). Drugs@FDA [www]. Food and Drug Administration (FDA). [updated 2005-02-22, cited 2019-03-06].

  4. Pickering TG, Levenstein M, Walmsley P. Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension Results of the HALT Study Hypertension and Lipid Trial Study Group. Am J Hypertens. 1994;7:848-52.

  5. Doggrell SA. After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2004;5:1957-64.

  6. Resorlu B, Bozkurt OF, Senocak C, Unsal A. Effectiveness of doxazosin in the management of lower ureteral stones in male and female patients. Int Urol Nephrol. 2011;43:645-9.

  7. Aydogdu O, Burgu B, Gucuk A, Suer E, Soygur T. Effectiveness of doxazosin in treatment of distal ureteral stones in children. J Urol. 2009;182:2880-4.

  8. van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs. 2006;66:287-301.

  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]

  1. Chung M, Vashi V, Puente J, Sweeney M, Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol. 1999;48:678-87.
  2. Kwon YH, Gwak HS, Yoon SJ, Chun IK. Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers. Drug Dev Ind Pharm. 2007;33:824-9.
  3. Clinical Pharmacology and Biopharmaceutics Review - CARDURA XL (doxazosin mesylate). Drugs@FDA [www]. Food and Drug Administration (FDA). [updated 2005-02-22, cited 2019-03-06].
  4. Pickering TG, Levenstein M, Walmsley P. Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension Results of the HALT Study Hypertension and Lipid Trial Study Group. Am J Hypertens. 1994;7:848-52.
  5. Doggrell SA. After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2004;5:1957-64.
  6. Resorlu B, Bozkurt OF, Senocak C, Unsal A. Effectiveness of doxazosin in the management of lower ureteral stones in male and female patients. Int Urol Nephrol. 2011;43:645-9.
  7. Aydogdu O, Burgu B, Gucuk A, Suer E, Soygur T. Effectiveness of doxazosin in treatment of distal ureteral stones in children. J Urol. 2009;182:2880-4.
  8. van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs. 2006;66:287-301.
  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]